Trial Profile

Phase 1 proof-of-concept study of DMR-001

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 13 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

12 Jan 2026 According to a Galecto Inc. media release, company raised 285 million dollars in a November PIPE, which is expected to support multiple data milestones, including phase 1 clinical proof-of-concept data for DMR-001 anticipated in 2027. The program remains on track for an expected IND submission, or equivalent, in mid-2026, with first-in-human dosing via subcutaneous administration anticipated thereafter.
03 Dec 2025 New trial record
10 Nov 2025 According to the Galecto Inc media release, An IND submission for DMR-001, with anticipated first-in-human administration via subcutaneous administration, is expected to occur in mid-2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com